Drawing for Serial No. 79230436

USPTO serial 79230436

Serial No. 79230436

Reviewed by CopyMark Law Group

Reg. 5759811Status 708Registered
Filing date
Status date
Registration date
May 28, 2019
Examiner
COLLOPY, DIANE PATRICIA
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with Serial No. 79230436?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Geza C Ziegler Jr

Geza C Ziegler Jr ZIEGLER IP LAW GROUP LLC.2000 Post Road, Suite 205Fairfield, CT 06824United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceuticals for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for inhalers, namely, medical pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders structured for delivery into the body by nebulizer, aerosol, or dry powder, via the lungs or via the nasal passageway; Dietary supplements; Pharmaceutical products for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ]SECTION 71 - CANCELLED—
009Vials for scientific purposes being laboratory equipment; Vials for laboratory use; Glass tubes for scientific purposes being laboratory equipment, none of the aforesaid being additive manufacturing devices or 3D devicesACTIVE—
010[ Surgical, medical, dental and veterinary apparatus and instruments, namely, injection devices for administering drugs sold empty; ] Medical apparatus for facilitating the inhalation of pharmaceutical preparations; [ Medical syringes sold empty for administering pharmaceuticals; ] Medical apparatus for introducing pharmaceutical preparations into the human body; Inhalers for medical use; Medical inhalers; [ Respiratory monitors for medical use; Apparatus for measuring lung function; Spirometers for examining the function of the lungs; Spirometers; Spirometer mouth pieces and tubing; breath gas analyzers for medical diagnostics; ] Replacement cartridges for medical inhalers sold empty; Nebulizer for administering medication in the form of a mist inhaled into the lungs, for treatment of asthma and respiratory diseasesACTIVE—
042Scientific and technological services, namely, research and design in the field of drug delivery via the lungs or via the nasal passageway; Scientific and technological design of new products for others; Advisory services relating to design engineering; Advisory services relating to product testing; Product design and development in the field of drug delivery via the lungs or via the nasal passageway; New product design services, namely, analysis and evaluation of product design; engineering design and consultancy; Professional consultancy relating to medical technology; engineering project management services, not for business purposes; Engineering research; Pharmaceutical research and development services; research and development for the pharmaceutical industry; Research relating to medicines; none of the aforesaid in relation to additive manufacturing services or 3D printing servicesACTIVE—
044Pharmaceutical compounding services; Pharmaceutical compounding consultation services; Pharmaceutical compounding advisory services; Medical services [ ; Veterinary services; Hygienic and beauty care for animals; Hygienic and beauty care for humans ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 14, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Oct 14, 2025NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Oct 14, 2025C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Oct 13, 2025EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Oct 3, 2025PR75POST REGISTRATION ACTION MAILED - SEC. 71 & 15—
Oct 3, 2025EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Aug 27, 2025PR75POST REGISTRATION ACTION MAILED - SEC. 71 & 15—
Aug 25, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 22, 2025ES75TEAS SECTION 71 & 15 RECEIVED—
May 16, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 16, 2025ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 16, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 16, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 16, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 16, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jun 16, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 28, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Sep 27, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 9, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 9, 2019FIMPFINAL DISPOSITION PROCESSED—
Aug 28, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 14, 2019ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
May 28, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 24, 2019CNEAEXAMINERS AMENDMENT MAILED—
Mar 8, 2019ISMRWITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST—
Feb 12, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 12, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 8, 2019GPNXNOTIFICATION PROCESSED BY IB—
Jan 23, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 23, 2019OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jan 23, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 21, 2018CNEAEXAMINERS AMENDMENT MAILED—
Dec 20, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 20, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Dec 20, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 19, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 19, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 19, 2018ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Dec 13, 2018LIMELIMITATION FROM THE IB - REQUEST EXAM REVIEW—
Nov 2, 2018LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Aug 1, 2018CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 1, 2018CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 26, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 25, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 25, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 20, 2018RFNTREFUSAL PROCESSED BY IB—
May 1, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 1, 2018RFRRREFUSAL PROCESSED BY MPU—
Apr 29, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 28, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 27, 2018DOCKASSIGNED TO EXAMINER—
Apr 24, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 20, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 19, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance